首页> 外文OA文献 >Screening for Colorectal Cancer. Part 1: Screening Tests and Program Design (3. updated edition)
【2h】

Screening for Colorectal Cancer. Part 1: Screening Tests and Program Design (3. updated edition)

机译:大肠癌的筛查。第1部分:筛选测试和程序设计(3.更新版)

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Central role of colonoscopy in screening for colorectal cancer: Colonoscopy is – irrespective of first line screening test – the final common pathway of all screening for colorectal cancer (CRC), and is used for biopsy and polyp removal. For a screening-test in the (healthy) general population colonoscopy is invasive and prone to (unlikely) serious complications. Screening-yield and rates of complications are strongly dependent on the individual operator and on quality assurance. As a result, training and continued education of endoscopists as well as monitoring of both detection and complication rates are key to high screening-quality. Effectiveness of screening for CRC: No data is currently available on the impact of CRC-screening on all-cause mortality. Four randomized controlled trials on screening for fecal occult blood as a first-line test (gFOBT) showed a relative risk reduction of 15% for disease-specific CRC-mortality. Absolute risk reduction was between 0.12-0.29%. Two large non-population based randomized controlled trial on once-only flexible sigmoidoscopy as a first-line screening-test showed a relative risk reduction of 31% and 22% (statistically not significant) for disease-specific CRC-mortality and a reduction of CRC incidence of 23% and 18%. Results from a large non-population based two round flexible sigmoidoscopy screening study showed a relative risk reduction of 26% of disease-specific CRC-mortality and a reduction of CRC incidence of 21%. Absolute risk reduction of CRC-mortality through flexible sigmoidoscopy was between 0.11-0.15%. Results from a population based randomized trials on flexible sigmoidoscopy are expected in 2013. To date there is no evidence from randomized controlled trials on CRC-screening using colonoscopy as a first-line screening test. Two randomized studies on screening with either colonoscopy or iFOBT as a first-line test will yield results starting ten years from now. There is only limited evidence on test characteristics (sensitivity, specificity, complication rates) in real life screening-settings. The ideal test strategy in CRC-screening is uncertain, the evidence base evolving. Choice of first-line screening-test: When considering first-line screening-tests on which to base an organized program, program sensitivity per invitee through the test's impact on participation in screening (and re-screening) is more important than single test-sensitivity per screened participant. Complications rates are to be taken into account. Program-sensitivity largely depends on participation rates. Recent developments in first-line screening tests include quantitative iFOBTs. CT-colonoscopy, capsule endoscopy and new molecular tests are not yet viable alternatives for use in population-based mass-screening. Improving screening-effectiveness: An upper age-limit for CRC-screening is recommended. An integrated screening-program combines screening with screening-relevant considerations in diagnosis, treatment and surveillance. Along with standardized documentation and regular evaluation an integrated program-design provides the quality necessary to consider screening average risk-populations. Giving thorough attention to the design of the surveillance regime is important, because its thresholds determine the numbers of surveillance-colonoscopies resulting from CRC-screening. Incremental implementation of a national population-based screening-program, with targeted research studies, pilot testing and incremental roll-out, like in the Netherlands, should be considered. Securing comprehensive program-financing: Population-based screening-programs require significant initial investment in overhead and sustainable financing of ongoing documentation, quality assurance and evaluation. Also, ongoing financing of both program- and provider-independent information dissemination to potential screening-participants enabling informed consent if or if not to participate in screening, and funds for regular program evaluation through an external institution need to be secured.
机译:结肠镜检查在结肠直肠癌筛查中的核心作用:结肠镜检查是–与一线筛查测试无关–是所有结肠直肠癌筛查(CRC)的最终通用途径,并用于活检和息肉清除。对于(健康)普通人群的筛查测试,结肠镜检查是侵入性的,容易(不太可能)发生严重并发症。筛查的效率和并发症的发生率在很大程度上取决于单个操作者和质量保证。结果,对内镜医师的培训和继续教育以及对检出率和并发症发生率的监控对于高筛查质量至关重要。 CRC筛查的有效性:目前尚无有关CRC筛查对全因死亡率影响的数据。四个随机对照试验筛选粪便潜血作为一线试验(gFOBT),结果表明,特定疾病的CRC死亡率相对风险降低了15%。绝对风险降低在0.12-0.29%之间。两项仅一次进行柔性乙状结肠镜检查的大型非人群随机对照试验作为一线筛查试验,结果表明,特定疾病的CRC死亡率相对危险度降低了31%和22%(统计学意义不显着),并且降低了CRC的发生率分别为23%和18%。一项基于大型非人群的两轮柔性乙状结肠镜筛查研究的结果表明,特定疾病的CRC死亡率相对风险降低了26%,CRC发生率降低了21%。通过柔性乙状结肠镜检查可将CRC死亡的绝对风险降低在0.11-0.15%之间。预计在2013年将进行基于人群的柔性乙状结肠镜检查的随机试验结果。迄今为止,尚无来自使用结肠镜检查作为一线筛查试验的CRC筛查的随机对照试验的证据。从结肠镜检查或iFOBT作为一线测试的两项随机研究将在十年后开始产生结果。在现实生活中的筛查环境中,关于测试特征(敏感性,特异性,并发症发生率)的证据很少。 CRC筛查的理想测试策略尚不确定,证据基础也在不断发展。一线筛选测试的选择:在考虑以一线筛选测试为基础的有组织程序的基础时,每个受邀者通过测试对参与筛选(和重新筛选)的影响对程序的敏感性比单项测试更为重要,每个被筛选参与者的敏感性。应考虑并发症发生率。计划的敏感性很大程度上取决于参与率。一线筛选测试的最新进展包括定量iFOBT。 CT结肠镜检查,胶囊内窥镜检查和新的分子检测尚不是可行的替代方法,可用于基于人群的大规模筛查。提高筛查效果:建议对CRC筛查使用年龄上限。集成的筛查程序将筛查与诊断,治疗和监测中与筛查相关的考虑因素结合在一起。连同标准化的文档和定期评估,集成的程序设计提供了考虑筛选平均风险人群所必需的质量。充分注意监视机制的设计很重要,因为它的阈值确定了由CRC筛选产生的监视结肠镜检查的数量。应当考虑像荷兰一样,逐步执行以人口为基础的全国性筛查计划,并进行有针对性的研究,试点试验和逐步推广。确保全面的计划融资:基于人群的筛查计划需要大量的初始投资,用于日常管理,持续的文档,质量保证和评估的间接费用和可持续融资。另外,需要为潜在的筛查参与者持续提供计划和独立于提供者的信息传播方面的资金,无论是否需要参加筛查,都要征得知情同意,并需要确保通过外部机构进行常规计划评估的资金。

著录项

  • 作者

    Patera N.; Schumacher I.;

  • 作者单位
  • 年度 2012
  • 总页数
  • 原文格式 PDF
  • 正文语种
  • 中图分类

相似文献

  • 外文文献
  • 中文文献
  • 专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号